SCHEMBL1363883

SCHEMBL1363883

CC(C)(C)OC(=O)c1ccc(OCCCCCCCCCC(=O)O)cc1.COC(=O)CCCCCCCCCOc1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.51
MAPT P10636 2/20 0.48
RAB9A P51151 1/20 0.47
PLA2G4B P0C869 2/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
LTA4H P09960 1/20 0.44
TSHR P16473 2/20 0.44
TP53 P04637 1/20 0.44
HDAC3 O15379 3/20 0.43
HDAC4 P56524 3/20 0.43
HDAC1 Q13547 3/20 0.43
HDAC7 Q8WUI4 3/20 0.43
HDAC2 Q92769 3/20 0.43
HDAC10 Q969S8 3/20 0.43
HDAC11 Q96DB2 3/20 0.43
HDAC8 Q9BY41 3/20 0.43
HDAC6 Q9UBN7 3/20 0.43
HDAC9 Q9UKV0 3/20 0.43
HDAC5 Q9UQL6 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26092045 0.95 MAPT (0.53) MAPTRAB9AGAAHTTLTA4H
SCHEMBL1743906 0.95 MAPT (0.53) MAPTRAB9AGAAHTTLTA4H
SCHEMBL558993 0.95 MAPT (0.53) MAPTRAB9AGAAHTTLTA4H
SCHEMBL4538607 0.92 PPARA (0.58) PPARAMAPTPLA2G4BGAATSHR
SCHEMBL20567660 0.92 PPARA (0.58) PPARAMAPTPLA2G4BGAATSHR
SCHEMBL26091641 0.92 PPARA (0.58) PPARAMAPTPLA2G4BGAATSHR
SCHEMBL4540684 0.92 PPARA (0.58) PPARAMAPTPLA2G4BGAATSHR
SCHEMBL1745096 0.92 PPARA (0.58) PPARAMAPTPLA2G4BGAATSHR
SCHEMBL2183439 0.92 PPARA (0.58) PPARAMAPTPLA2G4BGAATSHR
SCHEMBL557204 0.92 PPARA (0.58) PPARAMAPTPLA2G4BGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067362-B2 Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents NOVO NORDISK AS (DK) 2011-11-29 US disclosed
US-20080076705-A1 Insulin Derivatives NOVO NORDISK A/S (DK) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076705-A1 Insulin Derivatives IAPP, INSR, GPR119 PPARA 250/4885MAPT 4130/4885RAB9A 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.